GUIZHOU SANLI(SH:603439) Zheng Quan Zhi Xing·2025-06-12 10:23Core Viewpoint - Guizhou Sanli Pharmaceutical Co., Ltd. plans to sign technology transfer and development contracts with Guangdong Pharmaceutical University to enhance its product portfolio and market competitiveness through collaboration in drug research and development [1][5]. Group 1: Contract Overview - The company intends to sign a technology transfer contract for a fibrosis invention patent, successfully acquiring it for RMB 50 million on June 11, 2025 [2][3]. - The total amount for the proposed technology contracts is RMB 150 million, which is close to the board's review and disclosure threshold, prompting the management to voluntarily disclose this information [2][5]. - The company held board meetings on June 12, 2025, to approve the contracts, which do not require shareholder approval or constitute a major asset restructuring [2][5]. Group 2: Contract Details - The technology transfer contract involves the transfer of rights for the invention patent related to liver protection and fibrosis treatment, with the company becoming the sole patent owner [3][4]. - The payment structure for the patent transfer includes an initial payment of RMB 5 million within 10 working days after signing, followed by milestone-based payments [3][4]. - The technology development contract focuses on the joint development of SL&GDPU-001, a new traditional Chinese medicine, covering non-clinical and clinical research phases [4][5]. Group 3: Impact on the Company - The collaboration aims to leverage the company's industrial capabilities and the university's research resources, aligning with the company's long-term strategic goals [5]. - The contracts are not expected to significantly impact the company's current financial status or operating performance, with future impacts dependent on the progress of the projects [5].